https://www.urologytimes.com/view/2-year-update-sustains-promise-of-pembrolizumab-plus-abiraterone-in-chemo-na-ve-mcrpc
0
0
9/10/22 at 6:22pm
Organization
Urologytimes.com
Author
Miranda Lankas
41 words
0
Comments
The addition of pembrolizumab has the potential to improve upon standard care with abiraterone acetate plus prednisone in men with metastatic castration-resistant prostate cancer.
You are the first to view
Create an account
or login to join the discussion